Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives
Emanuele D’Amico, Aurora Zanghì, Matteo Gastaldi, et al.
Autoimmunity Reviews (2019) Vol. 18, Iss. 7, pp. 665-672
Closed Access | Times Cited: 40

Showing 26-50 of 40 citing articles:

Correlation between the Neutrophil-to-Lymphocyte Ratio and Multiple Sclerosis: Recent Understanding and Potential Application Perspectives
Qingqing Zhou, Rui Jia, Jingxia Dang
Neurology Research International (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 7
The Predictive Value of the Systemic Immune-inflammation Index as a New Prognostic Marker for Disability in Patients with Multiple Sclerosis
Hikmet Saçmacı, Tülin Aktürk, Nermin Tanık
Turkish Journal Of Neurology (2021) Vol. 27, Iss. 2, pp. 133-139
Open Access | Times Cited: 8
Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study
Emanuele D’Amico, Aurora Zanghì, Roberta Fantozzi, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 12, pp. 2563-2566
Open Access | Times Cited: 3
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment
Aurora Zanghì, Emanuele D’Amico, Francesco Patti
Expert Review of Neurotherapeutics (2020) Vol. 20, Iss. 8, pp. 771-782
Closed Access | Times Cited: 8
Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
Michael Auer, Anne Zinganell, Harald Hegen, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 6
Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment
Priyanka Devi-Marulkar, Carolina Moraes-Cabé, Pascal Campagne, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 4
Current Knowledge about CD3+CD20+ T Cells in Patients with Multiple Sclerosis
Borros Arneth
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8987-8987
Open Access
Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial
Mohammad Ali Sahraian, Roya Abolfazli, Vahid Shaygannejad, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials
Eoin Moloney, Atefeh Mashayekhi, Sakshi Sharma, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access
MOGAD and NMOSD: insights on patients’ radiological and laboratory findings from a single UAE center
Hamdan M Alzarooni, Jihad Inshasi, Ahmad Alawadhi, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access
MicroRNA Frontiers: Illuminating Early Detection Paths in Multiple Sclerosis
Morvarid Mohseni, Ghazal Behzad, Arezoo Farhadi, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 95, pp. 106237-106237
Closed Access
The screening and anti-Raji lymphoma effect of Chiloscyllium plagiosum anti-CD20 VNARs
Qingyu Ren, Yu Sheng, Ling Sun, et al.
Frontiers in Marine Science (2024) Vol. 11
Open Access
The predictive value of inflammatory biomarkers in the detection of multiple sclerosis attacks
Nafis VURAL, Murat Duyan, Ali SARIDAŞ, et al.
Emergency Care Journal (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 1
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study
Aurora Zanghì, Emanuele D’Amico, Francesco Patti, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 10, pp. 6069-6069
Open Access | Times Cited: 2
Case Report: The Use of Rituximab in Antibody-Negative Autoimmune Encephalitis
Soo-Hyun Park, Yong‐Chan Kim
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 2
Previous Page - Page 2

Scroll to top